Back to results
US 2018/0002414 A1Published application
Immunotherapy for Clearing Pathological Tau Conformers
AssigneeNew York University
InventorsEinar M. Sigurdsson, Ayodeji Asuni
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.
Claims17
A pharmaceutical composition comprising:
- (A) (1) a peptide that comprises an immunogenic Tau peptide, wherein said immunogenic Tau peptide is selected from the group of peptides consisting of SEQ ID NOs:1-20;
- or
- (2) an antibody, or a molecule comprising an epitope-binding portion thereof, that is capable of specifically binding to a misfolded and/or aggregate form of Tau protein with greater selectivity than to normal Tau protein;
- wherein said antibody and said epitope-binding portion thereof comprise the amino acid sequence of an epitope-binding portion of an antibody:
- (a) that is capable of binding to an epitope of said misfolded and/or aggregate form phosphorylated Tau that is present on said peptide (AX 1);
- and
- (b) that is capable of immunospecifically binding to phosphorylated Tau with greater selectivity than to non-phosphorylated Tau;
- and
- (B) a pharmaceutically acceptable carrier or diluent.
6 more elements
Dependencies are inferred from the claim text.